ACIP, RSV, XBI index, Gilead
Wish to keep on high of the science and politics driving biotech right this moment? Enroll to get our biotech publication in your inbox.
Good morning. Summer time is over and the market strikes yesterday made that clear. Extra on that and the most recent information beneath.
The necessity-to-know this morning
- Wave Life Sciences reported up to date outcomes from a mid-stage examine of its RNA-editing remedy for the intense lung situation alpha-1 antitrypsin deficiency, or AATD.
Gilead desires to hike worth of HIV meds distributed by states
Gilead Sciences is trying to considerably enhance the worth of a number of HIV remedies which might be distributed by state applications, threatening their monetary stability, my colleague Ed Silverman completely experiences.
This text is unique to STAT+ subscribers
Unlock this text — plus in-depth evaluation, newsletters, premium occasions, and information alerts.
Have already got an account? Log in
To learn the remainder of this story subscribe to STAT+.
